Glycaemic control and safety of insulin glargine (GLAR) in elderly patients with type 2 diabetes mellitus (T2DM): The GOAL A1C study

被引：0

作者：

Halter, J.

Kennedy, L.

Miller, M.

Herman, W.

机构：

[1] Univ Michigan, Geriatr Ctr, Div Geriatr Med, Ann Arbor, MI 48109 USA

[2] Univ Florida, Dept Med, Gainesville, FL USA

[3] Sanofi Aventis US, Bridgewater, MA USA

[4] Univ Michigan, Med Ctr, Dept Med, Ann Arbor, MI 48109 USA

来源：

DIABETOLOGIA | 2006年 / 49卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0987

引用

页码：602 / 603

页数：2

共 50 条

[1] Glycemic control and safety of insulin glargine (GLAR) in elderly patients with type 2 diabetes mellitus (T2DM): The GOAL A1C study
Halter, Jeffrey B.
Kennedy, Laurence
Herman, William H.
Miller, Michael E.
[J]. DIABETES, 2006, 55 : A114 - A115
[2] Glycemic control achieved with insulin glargine (GLAR) as "Add-on" therapy in type 2 diabetes mellitus (T2DM) is unaffected by age, race, diabetes duration or BMI: The GOAL A1C study
Kennedy, L
Herman, WH
Harris, A
Strange, P
[J]. DIABETES, 2005, 54 : A141 - A141
[3] Physician beliefs in efficacy of insulin glargine (GLAR) are associated with glucose control in type 2 diabetes (T2DM)
Herman, W.
Zhang, Q.
Kennedy, L.
[J]. DIABETOLOGIA, 2006, 49 : 527 - 528
[4] Similar glycemic control is achieved after discontinuation of thiazolidinediones (TZDs) and metformin (MET) in patients initiating insulin glargine (GLAR) as add-on therapy for type 2 Diabetes (T2DM): The GOAL A1C study
Herman, WH
Kennedy, L
Harris, A
Strange, P
[J]. DIABETES, 2005, 54 : A140 - A140
[5] Impact of active vs usual algorithmic insulin titration and point-of-care (POC) vs laboratory measurement of A1C on glycemic control in patients initiating insulin glargine (GLAR) for type 2 diabetes (T2DM): The GOAL A1C study
Kennedy, L
Herman, WH
Harris, A
Strange, P
[J]. DIABETES, 2005, 54 : A133 - A133
[6] Glycaemia optimization treatment (GOT): Glycaemic control and rate of severe hypoglycaemia for 5 different dosing algorithms of insulin glargine (GLAR) in patients with type 2 diabetes mellitus (T2DM)
Tanenberg, R. J.
Zisman, A.
Stewart, J. A.
[J]. DIABETOLOGIA, 2006, 49 : 601 - 602
[7] Psychosocial adjustment and outcomes of glycaemic control with basal insulin therapy in patients with type 2 diabetes mellitus (T2DM)
Tanenberg, R. J.
Zhang, Q.
Zisman, A.
[J]. DIABETOLOGIA, 2007, 50 : S435 - S436
[8] Glycaemic control and pregnancy outcomes in women with Type 2 diabetes mellitus (T2DM)
Pang, W. H.
Tan, Z.
Todd, D.
Halliday, M.
Gill, F.
Rhoads, M.
Sathiskumar, P.
Gallagher, A.
de Chazal, R.
Lawrence, I. G.
[J]. DIABETIC MEDICINE, 2008, 25
[9] Glycemia optimization treatment (GOT): Glycemic control and rate of severe hypoglycemia for five different dosing algorithms of insulin glargine (GLAR) in patients with type 2 diabetes mellitus (T2DM)
Tanenberg, Robert J.
Zisman, Ariel
Stewart, John
[J]. DIABETES, 2006, 55 : A135 - A135
[10] Free fatty acid (FFA) changes with insulin glargine (GLAR) vs thiazolidinediones (TZDs) according to baseline A1C in T2DM
Schwartz, Sherwyn
Cohen, Jay
Traylor, Louise
Rosenstock, Julio
[J]. DIABETES, 2007, 56 : A232 - A232

← 1 2 3 4 5 →